ABSTRACT
Several drugs with different modes and sites of action have been tried for the treatment of urodynamically demonstrated detrusor overactivity (DO), and the overactive bladder (OAB) syndrome.1,2 Antimuscarinic drugs are still first line pharmacotherapy, but have well known limitations.2 To be able to optimize treatment with current drug alternatives and to find new pharmacological treatment targets, further knowledge about the mechanisms of micturition is necessary.
